Serum Levels of Advanced Oxidation Protein Products and some Liver Function Markers in Chronic Myeloid Leukemia-Chronic Phase Patients Receiving Imatinib or Nilotinib
The treatment of chronic myeloid leukemia has witnessed substantial advancements by the introduction of tyrosine kinase inhibitors. Oxidative stress has been proposed as potential mechanism for resistance to their action. Simultaneously, oxidative stress has a crucial role in hepatic diseases and h...
Saved in:
Main Authors: | Ikhlas Khammas, Ali Abdulhussain Kasim, Bassam Francis |
---|---|
Format: | Article |
Language: | English |
Published: |
College of Pharmacy University of Baghdad
2025-06-01
|
Series: | Iraqi Journal of Pharmaceutical Sciences |
Subjects: | |
Online Access: | https://bijps.uobaghdad.edu.iq/index.php/bijps/article/view/2932 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01) -
Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01) -
Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
by: N. A. Avxentyev, et al.
Published: (2018-08-01) -
Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib
by: Rima Hajjo, et al.
Published: (2025-06-01) -
Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01)